Peptide inhibitors of calcium oxalate monohydrate crystallization and uses thereof

A method of inhibiting abnormal biomineralization in a subject in need thereof comprising:

• administering to the subject therapeutic effective amounts of a composition comprising
• at least one isolated polypeptide, and
• at least one pharmaceutically acceptable carrier;
• wherein the isolated polypeptide comprises an amino acid sequence selected from the group consisting of DDDAAAAADDDAAAAADD (SEQ ID NO:
• 1), AADAAAAADDAAAADAAA (SEQ ID NO:
• 2), ADAAADAADAADDAADAA (SEQ ID NO:
• 3), ADAADDAADAADDAAAAA (SEQ ID NO:
• 5), ADAAADDDAAADAAADDD (SEQ ID NO:
• 6), ADAAADDAAAAAAAADAA (SEQ ID NO:
• 7), ADAAADDAAADAAAADAA (SEQ ID NO:
• 8), ADAAADDAAADAAADDAA (SEQ ID NO:
• 9), ADAADAAADAADDAADAA (SEQ ID NO:
• 10), ADAADDAAAAAADAADAA (SEQ ID NO:
• 11), ADDAADAADAADDAADDA (SEQ ID NO:
• 12), AAEAAAAAEEAAAAEAAA (SEQ ID NO:
• 14), AEAAAEAAEAAEEAAEAA (SEQ ID NO:
• 15), AEAAAEEAAAEAAAAEAA (SEQ ID NO:
• 17), AEAAAEEAAAEAAAEEAA (SEQ ID NO:
• 18), AEAAEAAAEAAEEAAEAA (SEQ ID NO:
• 19), AEAAEEAAAAAAEAAEAA (SEQ ID NO:
• 20), AEEAAEAAEAAEEAAEEA (SEQ ID NO:
• 21), and AEEAEEAEEAEEAEEAEE (SEQ ID NO:
• 22), or consists of an amino acid sequence selected from the group consisting of ADAADAADAADAADAADA (SEQ ID NO:
• 4), ADADADADADADADADAD (SEQ ID NO:
• 13), AEAAEAAEAAEAAEAAEA (SEQ ID NO:
• 16), AEAEAEAEAEAEAEAEAE (SEQ ID NO:
• 23), and EEEEEEEEEEEEEEEEEE (SEQ ID NO:
• 24);
• and wherein the isolated polypeptide inhibits calcium oxalate monohydrate crystal growth.